Joel Greenblatt's NBIX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 168,572 shares of Neurocrine Biosciences, Inc. (NBIX) worth $23.91 M, representing 0.09% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in NBIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 60,106 shares. Largest reduction occurred in Q3 2024, reducing 22,962 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +32,218 | Add 23.63% | 168,572 | $141.83 |
| Q3 2025 | +45,225 | Add 49.63% | 136,354 | $140.38 |
| Q2 2025 | +60,106 | Add 193.75% | 91,129 | $125.69 |
| Q1 2025 | +25,309 | Add 442.93% | 31,023 | $110.60 |
| Q4 2024 | -9,603 | Reduce 62.70% | 5,714 | $136.50 |
| Q3 2024 | -22,962 | Reduce 59.99% | 15,317 | $115.22 |
| Q2 2024 | +32,975 | Add 621.70% | 38,279 | $137.67 |
| Q1 2024 | -234 | Reduce 4.23% | 5,304 | $137.92 |
| Q4 2023 | +480 | Add 9.49% | 5,538 | $131.76 |
| Q3 2023 | -355 | Reduce 6.56% | 5,058 | $112.50 |
| Q2 2023 | -2,180 | Reduce 28.71% | 5,413 | $94.30 |
| Q1 2023 | -236 | Reduce 3.01% | 7,593 | $101.22 |
| Q4 2022 | +2,204 | Add 39.18% | 7,829 | $119.44 |
| Q3 2022 | +29 | Add 0.52% | 5,625 | $106.13 |
| Q2 2022 | -1,427 | Reduce 20.32% | 5,596 | $97.39 |
| Q1 2022 | +4,465 | Add 174.55% | 7,023 | $93.69 |
| Q4 2021 | +2,558 | New Buy | 2,558 | $85.22 |
| Q4 2020 | -18,712 | Sold Out | 0 | $0.00 |
| Q3 2020 | +5,870 | Add 45.71% | 18,712 | $96.14 |
| Q2 2020 | -6,363 | Reduce 33.13% | 12,842 | $122.02 |
| Q1 2020 | -10,460 | Reduce 35.26% | 19,205 | $86.54 |
| Q4 2019 | +15,730 | Add 112.88% | 29,665 | $107.50 |
| Q3 2019 | +3,431 | Add 32.66% | 13,935 | $90.13 |
| Q2 2019 | -8,828 | Reduce 45.67% | 10,504 | $84.44 |
| Q1 2019 | +2,956 | Add 18.05% | 19,332 | $88.09 |
| Q4 2018 | -7,246 | Reduce 30.67% | 16,376 | $71.38 |
| Q3 2018 | +16,209 | Add 218.66% | 23,622 | $122.94 |
| Q2 2018 | +7,413 | New Buy | 7,413 | $98.21 |
Joel Greenblatt's Neurocrine Biosciences Investment FAQs
Joel Greenblatt first purchased Neurocrine Biosciences, Inc. (NBIX) in Q2 2018, acquiring 7,413 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Neurocrine Biosciences, Inc. (NBIX) for 28 quarters since Q2 2018.
Joel Greenblatt's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q2 2025, adding 91,129 shares worth $11.45 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 168,572 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $23.91 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.09% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 168,572 shares, as reported at the end of Q4 2025.